Intervention Protocol

Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis

  1. Jian Zhang1,
  2. Yousheng Xiao1,
  3. Lian Meng1,
  4. Xiaobo Yang2,
  5. Shengliang Shi1,*

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 11 FEB 2014

DOI: 10.1002/14651858.CD010968


How to Cite

Zhang J, Xiao Y, Meng L, Yang X, Shi S. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010968. DOI: 10.1002/14651858.CD010968.

Author Information

  1. 1

    The First Affiliated Hospital, Guangxi Medical University, Department of Neurology, Nanning, Guangxi, China

  2. 2

    Guangxi Medical University, Department of Occupational Health and Environmental Health, School of Public Health, Nanning, Guangxi, China

*Shengliang Shi, Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Road, Nanning, Guangxi, 530021, China. ssl_1964@163.com. sslno1@yahoo.com.cn.

Publication History

  1. Publication Status: New
  2. Published Online: 11 FEB 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of patients with relapsing-remitting multiple sclerosis to prevent disease activity.